Dr. Xing  Wu
My Social Links

Dr. Xing Wu

Research Scientist
University of Basel, Basel, Switzerland


Highest Degree
Ph.D. in Biochemistry from University of Basel, Switzerland

Share this Profile

Area of Interest:

Chemistry
100%
Bioactive Compounds
62%
Organic Chemistry
90%
Pharmacology
75%
Biochemistry
55%

Research Publications in Numbers

Books
0
Chapters
0
Articles
0
Abstracts
0

Selected Publications

  1. Hasinoff, B.B., X. Wu, D. Patel, R. Kanagasabai, S. Karmahapatra and J.C. Yalowich, 2016. Mechanisms of action and reduced cardiotoxicity of pixantrone; a topoisomerase II targeting agent with cellular selectivity for the topoisomerase IIα isoform. J. Pharmacol. Exp. Therapeut., 356: 397-409.
    CrossRef  |  Direct Link  |  
  2. Hasinoff, B.B., X. Wu, A.A. Yadav, D. Patel and H. Zhang et al., 2015. Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II). Biochem. Pharmacol., 93: 266-276.
    CrossRef  |  Direct Link  |  
  3. Hasinoff, B.B., X. Wu, J.L. Nitiss, R. Kanagasabai and J.C. Yalowich, 2012. The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II. Biochem. Pharmacol., 84: 1617-1626.
    CrossRef  |  Direct Link  |  
  4. Wu, X., J.C. Yalowich and B.B. Hasinoff, 2011. Cadmium is a catalytic inhibitor of DNA topoisomerase II. J. Inorg. Biochem., 105: 833-838.
    CrossRef  |  Direct Link  |  
  5. Wu, X., H. Liang, K.A. O’Hara, J.C. Yalowich and B.B. Hasinoff, 2008. Thiol-modulated mechanisms of the cytotoxicity of thimerosal and inhibition of DNA topoisomerase IIα. Chem. Res. Toxicol., 21: 483-493.
    CrossRef  |  Direct Link  |  
  6. Hasinoff, B.B., X. Wu, J.C. Yalowich, V. Goodfellow, R.S. Laufer, O. Adedayo and G.I. Dmitrienko, 2006. Kinamycins A and C, bacterial metabolites that contain an unusual diazo group, as potential new anticancer agents: Antiproliferative and cell cycle effects. Anti-Cancer Drugs, 17: 825-837.
    CrossRef  |  Direct Link  |  
  7. Hasinoff, B.B., X. Wu, A. Begleiter, L.J. Guziec and F. Guziec et al., 2006. Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II. Cancer Chemother. Pharmacol., 57: 221-233.
    CrossRef  |  Direct Link  |  
  8. Wu, X. and B.B. Hasinoff, 2005. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species. Anti-Cancer Drugs, 16: 93-99.
    Direct Link  |  
  9. Hasinoff, B.B., X. Wu, O.V. Krokhin, W. Ens and K.G. Standing et al., 2005. Biochemical and proteomics approaches to characterize topoisomerase IIα cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIα. Mol. Pharmacol., 67: 937-947.
    CrossRef  |  Direct Link  |  
  10. Wu, X., D. Patel and B.B. Hasinoff, 2004. The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycin. J. Inorg. Biochem., 98: 1818-1823.
    CrossRef  |  Direct Link  |  
  11. Hasinoff, B.B., X. Wu and Y. Yang, 2004. Synthesis and characterization of the biological activity of the cisplatin analogs, cis-PtCl2(dexrazoxane) and cis-PtCl2(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186). J. Inorg. Biochem., 98: 616-624.
    CrossRef  |  Direct Link  |  
  12. Wu, X. and H. Lee, 2002. Human Dbf4/ASK promoter is activated through the Sp1 and MluI cell-cycle box (MCB) transcription elements. Oncogene, 21: 7786-7796.
    CrossRef  |  Direct Link  |